No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
COGT Cogent Biosciences
- 8.425
- -0.555-6.18%
Close Jun 14 16:00 ET
- 8.430
- +0.005+0.06%
Post 16:36 ET
921.22MMarket Cap-3383P/E (TTM)
8.990High8.070Low1.03MVolume8.880Open8.980Pre Close8.65MTurnover1.34%Turnover RatioLossP/E (Static)109.34MShares13.36052wk High4.60P/B649.30MFloat Cap3.67052wk Low--Dividend TTM77.07MShs Float174.200Historical High--Div YieldTTM10.25%Amplitude1.904Historical Low8.405Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $18
Needham analyst Ami Fadia maintains $Cogent Biosciences(COGT.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 44.4% and a tot
Express News | Cogent Biosciences Reveals Additional Data From Part 1 Of Its Ongoing SUMMIT Clinical Trial Evaluating The Selective KIT D816V Inhibitor, Bezuclastinib, In Patients With Nonadvanced Systemic Mastocytosis
Express News | Cogent Biosciences Inc: Recommended Dose of 100 Mg Demonstrates a Favorable Safety and Tolerability Profile
Express News | Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
Express News | Cogent Biosciences-on Track to Complete Enrollment in Registration-Directed Summit Part 2 Study in Q2 of 2025, Report Topline Results by Year-End 2025
Express News | Cogent Biosciences Inc - Patients Treated With 100 Mg Bezuclastinib Showed Substantial Reduction in Their Most Severe Symptoms and Mast Cell Reactions
Comments
$Cogent Biosciences(COGT.US$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
$Cogent Biosciences(COGT.US$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
1
5
$Cogent Biosciences(COGT.US$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
1
Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
$Cogent Biosciences(COGT.US$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago
GlobeNewswire· 30 mins ago
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg